The Effects of C-type Natriuretic Peptide on Human Forearm Blood Vessels
NCT ID: NCT01075776
Last Updated: 2020-05-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
NA
INTERVENTIONAL
2020-01-31
2023-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Targeting Central Pulsatile Hemodynamics in Chronic Kidney Disease
NCT02791906
Bicarbonate v Saline to Prevent Contrast Nephropathy
NCT00384995
A Prospective, Randomized TrialComparing Oral N-Acetylcysteine and Intravenous Sodium Bicarbonate
NCT00579995
Contrast Agent-associated Nephrotoxicity in Intensive Care Unit Patients
NCT01017796
Myocardial Salvage and Contrast Dye Induced Nephropathy Reduction by N-Acetylcystein
NCT00463749
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
BASIC_SCIENCE
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
CNP
Infusion of CNP prior to IR injury
C-type natriuretic peptide (CNP)
360 pmol/min for 15 minutes intra-arterially
Acetylcholine
2 stepped infusions for a total 9min per limb, totalling 1.05micromoles per limb
Saline
Effect of saline infusion prior to IR injury
Saline
Sodium Chloride 0.9% intra-arterially 0.5ml/min
Acetylcholine
2 stepped infusions for a total 9min per limb, totalling 1.05micromoles per limb
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
C-type natriuretic peptide (CNP)
360 pmol/min for 15 minutes intra-arterially
Saline
Sodium Chloride 0.9% intra-arterially 0.5ml/min
Acetylcholine
2 stepped infusions for a total 9min per limb, totalling 1.05micromoles per limb
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Unwillingness to sign consent form
* Use of non-OCP medications
* Hypertension on examination of the blood pressure
18 Years
45 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University College, London
OTHER
Queen Mary University of London
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Amrita Ahluwalia
Professor of Vascular Pharmacology
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ahluwalia Amrita, BSc PhD
Role: PRINCIPAL_INVESTIGATOR
Queen Mary University London
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Queen Mary University London
London, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
007143
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.